We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Halozyme to Present at Upcoming Investor Conferences PR Newswire SAN DIEGO, Nov. 27, 2024 SAN DIEGO, Nov. 27, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today...
Halozyme Withdraws Proposal to Acquire Evotec Following Evotec's Unwillingness to Engage in Discussions PR Newswire SAN DIEGO, Nov. 22, 2024 SAN DIEGO, Nov. 22, 2024 /PRNewswire/ -- Halozyme...
Halozyme Confirms Proposal to Combine with Evotec for โฌ11.00 Per Share in an All-Cash Transaction PR Newswire SAN DIEGO, Nov. 14, 2024 Combination Would Create a Global Innovative Services...
HALOZYME REPORTS THIRD QUARTER 2024 FINANCIAL AND OPERATING RESULTS PR Newswire SAN DIEGO, Oct. 31, 2024 Total Revenue Increased 34%ย YOY to $290 million and Royalty Revenue Increased 36% YOY to...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE PR Newswire SAN DIEGO, Oct. 24, 2024 Company Projects No Impact on U.S. or European Royalty Revenues from DARZALEX...
Halozyme to Report Third Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO, Oct. 23, 2024 SAN DIEGO, Oct. 23, 2024 /PRNewswire/ --ย Halozyme Therapeutics, Inc. (NASDAQ: HALO...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | -6.98 | -99.7142857143 | 7 | 9.2 | 0.015 | 1227941 | 0.49501208 | CS |
260 | -0.405 | -95.2941176471 | 0.425 | 35 | 0.015 | 2669071 | 0.36947363 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions